WAVEMAN · COMPANY

ORMP · Oramed Pharmaceuticals Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

ORMP

Name: ORAMED PHARMACEUTICALS INC. (ORMP) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

ORAMED PHARMACEUTICALS INC.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001176309

FORM 144 · 2☆ WATCH

INSIDER NET · 180D

-$942.2K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+49.3%

XBRL, annual

NET MARGIN

3202.5%

CONVERSIONS · 180D

codes C/M, not in net · $184.5K priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$942.2K over 180 days

-$942.2K over 90 days

below 59% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

50 funds added or opened last quarter

below 55% of Pharma & Biotech

REVENUE

+49.3% year over year

more than 78% of Pharma & Biotech

MARGIN

3202.5% net margin

the highest in Pharma & Biotech

BUYBACKS

$4.7M repurchased, FY to 2025-12-31

below 78% of Pharma & Biotech

SHORT

2.0% of shares outstanding short · 5.7 days to cover · settled 2026-07-31

below 64% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

50 funds added or opened positions in the latest 13F quarter, of 85 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +153.0%

+153.0%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $942.2K sold by insiders over 180 days, 50 funds added last quarter, $1.1M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, ORAMED PHARMACEUTICALS INC. insiders sold a net $942.2K of stock across 16 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

Gabay Avraham

Chief Financial Officer

SELL

2026-07-01

73,360.0

$330.7K

Hexter Joshua

COO & CBO

SELL

2026-07-01

137,000.0

$611.4K

Mayer Arie

Director

BUY

2023-04-04

3,800.0

$8.4K

Mayer Arie

Director

BUY

2023-04-03

5,009.0

$11.1K

KIDRON NADAV

President and CEO

BUY

2023-03-16

26,000.0

$53.0K

16 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 11 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

MERCER GLOBAL ADVISORS INC /ADV

5,721,080.0 sh

$27.5M

Aquamarine Financial (Cayman) Ltd

2,512,175.0 sh

$12.1M

Gem Investment Advisors, LLC

1,998,802.0 sh

$9.6M

BlackRock, Inc.

1,608,111.0 sh

$7.7M

Murchinson Ltd.

1,290,294.0 sh

$6.2M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Gabay Avraham

FILED 2026-07-01

$449.1K

Hexter Joshua

FILED 2026-07-01

$659.0K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Nationwide Bailard Small Cap Value Fund

$126.0K POSITION · AS OF 2026-04-30

0.1%

iShares Micro-Cap ETF

$280.8K POSITION · AS OF 2026-03-31

0.0%

1290 VT Micro Cap Portfolio

$20.7K POSITION · AS OF 2026-03-31

0.0%

Avantis U.S. Small Cap Equity ETF

$61.3K POSITION · AS OF 2026-02-28

0.0%

Victory Extended Market Index Fund

$13.6K POSITION · AS OF 2026-04-30

0.0%

LVIP Dimensional U.S. Core Equity 2 Fund

$9.1K POSITION · AS OF 2026-03-31

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Executive pay vs shareholder return · Mr. Nadav Kidron

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$4.8M

$2.0M

+18%

—

2024

$2.1M

$1.3M

+5%

—

2023

$1.7M

$265.8K

$918.9K

-81%

—

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$2.0M	—	$1.3M	$2.7M
GROSS PROFIT	$13.0K	—	—	—
OPERATING INCOME	$-15.1M	$-12.8M	$-15.8M	$-40.6M
NET INCOME	$75.3K	$-15.9K	$5.1K	$-36.6M
EPS (DILUTED)	1.50	-0.48	0.14	-0.94
OPERATING CASH FLOW	$-9.1M	$-8.4M	$-10.3M	$-27.9M
CASH	$45.9M	$54.4M	$9.1M	$40.5M
LONG-TERM DEBT	—	—	—	$25.0K
BUYBACKS	$4.7M	$2.5M	—	—

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE